Deutsche Bank Aktiengesellschaft reiterated their buy rating on shares of GSK (LON:GSK – Get Rating) in a report issued on Tuesday morning, Marketbeat Ratings reports. The brokerage currently has a GBX 1,700 ($21.01) price target on the stock.
Several other analysts have also issued reports on the company. Jefferies Financial Group set a GBX 1,575 ($19.46) target price on GSK in a research note on Wednesday, February 1st. JPMorgan Chase & Co. reiterated an underweight rating on shares of GSK in a report on Tuesday, May 9th. The Goldman Sachs Group set a GBX 2,000 ($24.72) price target on GSK in a research note on Monday, March 6th. UBS Group set a GBX 1,245 ($15.39) price target on GSK in a report on Wednesday, February 1st. Finally, Berenberg Bank reaffirmed a buy rating and issued a GBX 1,730 ($21.38) target price on shares of GSK in a report on Wednesday, April 19th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat, GSK currently has a consensus rating of Hold and a consensus target price of GBX 1,573.33 ($19.44).
GSK Trading Down 0.9 %
Shares of GSK stock opened at GBX 1,358.40 ($16.79) on Tuesday. GSK has a 52 week low of GBX 1,280.92 ($15.83) and a 52 week high of GBX 2,280.50 ($28.18). The company has a debt-to-equity ratio of 184.80, a quick ratio of 0.73 and a current ratio of 0.95. The stock has a 50 day moving average price of GBX 1,453.92 and a two-hundred day moving average price of GBX 1,437.84. The stock has a market capitalization of £55.02 billion, a PE ratio of 1,257.80, a price-to-earnings-growth ratio of 2.04 and a beta of 0.28.
GSK Increases Dividend
The business also recently disclosed a dividend, which will be paid on Thursday, July 13th. Shareholders of record on Thursday, May 18th will be paid a dividend of GBX 14 ($0.17) per share. This is a boost from GSK’s previous dividend of $13.75. This represents a yield of 0.93%. The ex-dividend date of this dividend is Thursday, May 18th. GSK’s payout ratio is presently 5,137.61%.
Insider Activity
In other news, insider Iain Mackay purchased 200 shares of the stock in a transaction that occurred on Tuesday, April 18th. The stock was purchased at an average price of GBX 1,493 ($18.45) per share, for a total transaction of £2,986 ($3,690.06). In other GSK news, insider Iain Mackay purchased 200 shares of GSK stock in a transaction dated Tuesday, April 18th. The shares were acquired at an average cost of GBX 1,493 ($18.45) per share, with a total value of £2,986 ($3,690.06). Also, insider Jonathan Symonds purchased 2,100 shares of GSK stock in a transaction dated Monday, March 20th. The shares were acquired at an average cost of GBX 1,399 ($17.29) per share, for a total transaction of £29,379 ($36,306.23). Over the last 90 days, insiders have acquired 2,309 shares of company stock valued at $3,249,586. 1.75% of the stock is currently owned by insiders.
About GSK
(Get Rating)
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
See Also
Receive News & Ratings for GSK Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GSK and related companies with MarketBeat.com’s FREE daily email newsletter.